Abstract
Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some other internal parasite species. Another ML, moxidectin, became available in 1997 as a gel formulation for oral administration. The parasiticidal activity of this compound is similar to ivermectin except efficacy is less on the common bot (Gastrophilus intestinalis) but high on encysted small strongyles. Recently however lower than initial activity on ascarids and small strongyles has been found for both ivermectin and moxidectin.
Keywords: Bots, ectoparasites, efficacy, equids, internal parasites, ivermectin, macrocyclic lactones, moxidectin, nematodes, toxicosis, treatment
Current Pharmaceutical Biotechnology
Title:Macrocyclic Lactones for Parasite Control in Equids
Volume: 13 Issue: 6
Author(s): E. T. Lyons and S. C. Tolliver
Affiliation:
Keywords: Bots, ectoparasites, efficacy, equids, internal parasites, ivermectin, macrocyclic lactones, moxidectin, nematodes, toxicosis, treatment
Abstract: Macrocyclic lactones (MLs) revolutionized parasite control in horses and other animals. They are unique in that they are effective against arthropods and nematodes. The first of the widely used avermectins was ivermectin. In 1983, it was marketed for use in horses as an injectable formulation but was withdrawn in 1984 after about a year and half on the market because of adverse problems. It was replaced by a paste formulation and an oral/stomach tube liquid formulation. Ivermectin is highly active on bots, ascarids, large and small strongyles, pinworms, strongyloides, stomach worms, and some other internal parasite species. Another ML, moxidectin, became available in 1997 as a gel formulation for oral administration. The parasiticidal activity of this compound is similar to ivermectin except efficacy is less on the common bot (Gastrophilus intestinalis) but high on encysted small strongyles. Recently however lower than initial activity on ascarids and small strongyles has been found for both ivermectin and moxidectin.
Export Options
About this article
Cite this article as:
T. Lyons E. and C. Tolliver S., Macrocyclic Lactones for Parasite Control in Equids, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399310
DOI https://dx.doi.org/10.2174/138920112800399310 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
Current Neuropharmacology Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews Aquaporins and Glia
Current Neuropharmacology Thermotropic and Spectroscopic Behavior of Skin: Relationship with Percutaneous Permeation Enhancement
Current Drug Delivery Pharmacological and Biological Activities of Benzazepines: An Overview
Current Bioactive Compounds Nano Traditional Chinese Medicine: Current Progresses and Future Challenges
Current Drug Targets Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Stem Cells for Microenvironmental Modulation and Retinal Regeneration
Current Tissue Engineering (Discontinued) The Role of Platelets in Athero-Thrombotic Events
Current Pharmaceutical Design Human Anthrax as a Re-Emerging Disease
Recent Patents on Anti-Infective Drug Discovery Modulation of Neuro-Inflammation and Vascular Response by Oxidative Stress Following Cerebral Ischemia-Reperfusion Injury
Current Medicinal Chemistry Albumin Induces Neuroprotection Against Ischemic Stroke by Altering Toll-Like Receptor 4 and Regulatory T Cells in Mice
CNS & Neurological Disorders - Drug Targets Targeting Peroxisome Proliferator-Activated Receptor Gamma for Generation of Antidiabetic Drug
Current Diabetes Reviews Cannabinoids: Between Neuroprotection and Neurotoxicity
Current Drug Targets - CNS & Neurological Disorders Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Parasite Prolyl Oligopeptidases and the Challenge of Designing Chemotherapeuticals for Chagas Disease, Leishmaniasis and African Trypanosomiasis
Current Medicinal Chemistry Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design